How aumolertinib changes midazolam levels in lung cancer patients
Part of Cancer, Lungs & breathing clinical trials.
This study tests how a lung cancer pill called aumolertinib affects the levels of another drug (midazolam) in your body. It is for people with advanced NSCLC whose tumors have specific EGFR gene changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a confirmed diagnosis of non-small cell lung cancer (NSCLC) that is locally advanced or has spread (Stage IIIB, IIIC, or IV).
- Your tumor must have one of these EGFR mutations: either the exon 19 deletion or L858R (if you haven't had prior treatment), or the T790M mutation (if you've received a first-generation EGFR-targeted pill and it stopped working).
- You must be in fairly good physical condition (able to do daily activities without help, ECOG score 0 or 1) and expected to live at least 12 weeks.
- You cannot have unstable brain metastases, active infections (like hepatitis B or HIV), or uncontrolled health problems.
- You must not have a history of lung inflammation (interstitial lung disease) or certain eye conditions (like acute angle-closure glaucoma).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking aumolertinib (a pill that targets specific EGFR mutations) after lung cancer surgery helps prevent the cancer from coming back. It is for people with early-stage non-small cell lung cancer that has an EGFR mutation and has been completely removed.
This study tests a new targeted therapy, Aumolertinib, for adults with a specific type of advanced lung cancer (non-small cell lung cancer) that has certain genetic changes (EGFR mutations). The goal is to see if the drug can shrink or slow the cancer.
This trial compares two targeted therapy pills, aumolertinib and osimertinib, for people with a specific EGFR mutation in advanced non-small-cell lung cancer that has spread. Both drugs are designed to block cancer growth signals. The study aims to see which one works better as a first treatment.
This study tests two combinations of drugs to see which works better for people with a specific type of lung cancer that has a change in the EGFR gene. The treatments may help shrink tumors or slow their growth.
This study tests three different targeted pills (osimertinib, afatinib, dacomitinib) in people with advanced EGFR-mutated lung cancer who haven't had targeted therapy before. The goal is to find which pill works best and has the fewest side effects.
This study tests an oral pill (DZD9008) that targets a specific genetic change in lung cancer called EGFR. If you have this mutation, the drug may shrink your tumor or slow its growth, especially if other treatments have stopped working or caused side effects.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.